Skip to main content

[M24-311] A Phase 2, Randomized Study to Evaluate Safety, Efficacy, and Optimal Dose of ABBV-400 in Combination with Fluorouracil, Folinic Acid, and Bevacizumab in Previously Treated Subjects with Unresectable Metastatic Colorectal Cancer

Clinical Trial Grant
Duke Scholars

Awarded By

AbbVie Inc.

Start Date

October 4, 2023

End Date

December 1, 2028
 

Awarded By

AbbVie Inc.

Start Date

October 4, 2023

End Date

December 1, 2028